News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,702 Results
Type
Article (55377)
Company Profile (401)
Press Release (633924)
Multimedia
Podcasts (118)
Webinars (12)
Section
Business (189327)
Career Advice (3249)
Deals (32478)
Drug Delivery (112)
Drug Development (83134)
Employer Resources (182)
FDA (16188)
Job Trends (14424)
News (328964)
Policy (32091)
Tag
Academia (2831)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (89)
Alliances (49518)
ALS (97)
Alzheimer's disease (1450)
Antibody-drug conjugate (ADC) (148)
Approvals (16161)
Artificial intelligence (286)
Autoimmune disease (27)
Automation (16)
Bankruptcy (310)
Best Places to Work (11577)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (306)
Bladder cancer (83)
Brain cancer (30)
Breast cancer (295)
Cancer (2380)
Cardiovascular disease (194)
Career advice (2746)
Career pathing (34)
CAR-T (172)
Cell therapy (483)
Cervical cancer (21)
Clinical research (67289)
Collaboration (886)
Compensation (497)
Complete response letters (29)
COVID-19 (2657)
CRISPR (47)
C-suite (251)
Cystic fibrosis (107)
Data (2240)
Decentralized trials (2)
Denatured (41)
Depression (50)
Diabetes (286)
Diagnostics (6127)
Digital health (18)
Diversity (7)
Diversity, equity & inclusion (45)
Drug discovery (134)
Drug pricing (110)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (75742)
Editorial (44)
Employer branding (23)
Employer resources (158)
Events (114364)
Executive appointments (724)
FDA (17457)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (780)
Gene editing (115)
Generative AI (28)
Gene therapy (355)
GLP-1 (789)
Government (4647)
Grass and pollen (6)
Guidances (58)
Healthcare (19254)
Huntington's disease (23)
IgA nephropathy (30)
Immunology and inflammation (140)
Indications (30)
Infectious disease (2796)
Inflammatory bowel disease (151)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (98)
Interviews (636)
IPO (15446)
IRA (46)
Job creations (3308)
Job search strategy (2246)
Kidney cancer (11)
Labor market (36)
Layoffs (480)
Leadership (24)
Legal (7346)
Liver cancer (74)
Lung cancer (338)
Lymphoma (158)
Machine learning (7)
Management (63)
Manufacturing (328)
MASH (72)
Medical device (12811)
Medtech (12815)
Mergers & acquisitions (17621)
Metabolic disorders (747)
Multiple sclerosis (82)
NASH (21)
Neurodegenerative disease (105)
Neuropsychiatric disorders (33)
Neuroscience (2031)
NextGen: Class of 2025 (6760)
Non-profit (4718)
Now hiring (30)
Obesity (400)
Opinion (269)
Ovarian cancer (78)
Pain (95)
Pancreatic cancer (82)
Parkinson's disease (158)
Partnered (22)
Patents (240)
Patient recruitment (111)
Peanut (48)
People (53490)
Pharmaceutical (81)
Pharmacy benefit managers (20)
Phase I (21009)
Phase II (29544)
Phase III (22197)
Pipeline (1212)
Policy (157)
Postmarket research (2735)
Preclinical (9082)
Press Release (68)
Prostate cancer (113)
Psychedelics (37)
Radiopharmaceuticals (266)
Rare diseases (426)
Real estate (5486)
Recruiting (72)
Regulatory (22290)
Reports (38)
Research institute (2498)
Resumes & cover letters (516)
Rett syndrome (5)
RNA editing (5)
RSV (41)
Schizophrenia (78)
Series A (135)
Series B (89)
Service/supplier (10)
Sickle cell disease (58)
Special edition (18)
Spinal muscular atrophy (155)
Sponsored (33)
Startups (3413)
State (2)
Stomach cancer (16)
Supply chain (71)
Tariffs (40)
The Weekly (75)
Vaccines (716)
Venture capitalists (42)
Weight loss (280)
Women's health (36)
Worklife (20)
Date
Today (164)
Last 7 days (868)
Last 30 days (2666)
Last 365 days (33712)
2025 (10959)
2024 (36033)
2023 (40387)
2022 (51155)
2021 (55508)
2020 (53753)
2019 (46853)
2018 (35506)
2017 (32859)
2016 (32747)
2015 (37749)
2014 (31014)
2013 (26388)
2012 (27501)
2011 (27760)
2010 (26109)
Location
Africa (949)
Alabama (56)
Alaska (7)
Arizona (190)
Arkansas (14)
Asia (40177)
Australia (7018)
California (6118)
Canada (1992)
China (542)
Colorado (266)
Connecticut (283)
Delaware (147)
Europe (93531)
Florida (900)
Georgia (208)
Idaho (56)
Illinois (565)
India (29)
Indiana (300)
Iowa (11)
Japan (160)
Kansas (100)
Kentucky (25)
Louisiana (11)
Maine (53)
Maryland (881)
Massachusetts (4726)
Michigan (226)
Minnesota (379)
Mississippi (1)
Missouri (80)
Montana (27)
Nebraska (23)
Nevada (57)
New Hampshire (65)
New Jersey (1725)
New Mexico (30)
New York (1736)
North Carolina (1052)
North Dakota (8)
Northern California (2643)
Ohio (204)
Oklahoma (14)
Oregon (35)
Pennsylvania (1363)
Puerto Rico (11)
Rhode Island (33)
South America (1275)
South Carolina (21)
Southern California (2299)
Tennessee (99)
Texas (887)
United States (23256)
Utah (172)
Virginia (150)
Washington D.C. (62)
Washington State (575)
West Virginia (3)
Wisconsin (54)
689,702 Results for "the leukemia and lymphoma society".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
The Leukemia & Lymphoma Society Denounces Federal Actions that Threaten Cancer Patients
February 11, 2025
·
2 min read
BioCapital
Eilean Therapeutics Joins The Leukemia & Lymphoma Society’s Groundbreaking Beat AML® Master Clinical Trial
Eilean Therapeutics AU Pty Ltd has joined The Leukemia & Lymphoma Society in the groundbreaking collaborative Beat AML® Master Clinical Trial.
June 11, 2024
·
4 min read
The Leukemia & Lymphoma Society Welcomes Five Members to its Board of Directors
The Leukemia & Lymphoma Society named five new members to its board of directors effective July 1, 2024, whose diverse experience and interests will be instrumental in helping the organization carry out its mission to cure blood cancer and improve the quality of life of all patients and their families.
July 1, 2024
·
5 min read
Press Releases
The Leukemia & Lymphoma Society Names Lore Gruenbaum, Ph.D., New Chief Scientific Officer
January 14, 2025
·
3 min read
Business
The Leukemia & Lymphoma Society and Tasso Announce Partnership to Advance Blood Cancer Research
The Leukemia & Lymphoma Society®, a global leader in the fight against blood cancer, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, announced a collaboration to accelerate blood cancer research.
May 30, 2024
·
3 min read
Press Releases
THE LEUKEMIA & LYMPHOMA SOCIETY ANNOUNCES REIMAGINED EXECUTIVE LEADERSHIP TEAM
October 29, 2024
·
5 min read
Pharm Country
The Leukemia & Lymphoma Society is Accepting Applications for Up to $2.5 Million in Funding Through its Equity in Access Research Program
The Leukemia & Lymphoma Society’s Equity in Access Research Program announced the opening of its application process for the 2025 funding cycle.
May 22, 2024
·
3 min read
Business
Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients
Jasper Health is proud to announce a strategic collaboration with The Leukemia & Lymphoma Society (LLS), a global leader in the fight against blood cancer.
March 13, 2024
·
2 min read
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
Enterome announced that it received a €3 million investment from The Leukemia & Lymphoma Society’s Therapy Acceleration Program®.
October 30, 2023
·
6 min read
Genetown
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®
Rgenta Therapeutics announced that it was selected by The Leukemia & Lymphoma Society as a new Therapy Acceleration Program® portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company’s therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
January 30, 2024
·
3 min read
1 of 68,971
Next
